Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2
D. Schultz, Robert M. Johnson, Kasirajan Ayyanathan, et al.
Nature (2022) Vol. 604, Iss. 7904, pp. 134-140
Open Access | Times Cited: 169

Showing 1-25 of 169 citing articles:

SARS-CoV-2 reservoir in post-acute sequelae of COVID-19 (PASC)
Amy D. Proal, Michael B. VanElzakker, Soo Aleman, et al.
Nature Immunology (2023) Vol. 24, Iss. 10, pp. 1616-1627
Open Access | Times Cited: 171
Accurate prediction of molecular properties and drug targets using a self-supervised image representation learning framework
Xiangxiang Zeng, Hongxin Xiang, Linhui Yu, et al.
Nature Machine Intelligence (2022) Vol. 4, Iss. 11, pp. 1004-1016
Open Access | Times Cited: 130
Long COVID endotheliopathy: hypothesized mechanisms and potential therapeutic approaches
Jasimuddin Ahamed, Jeffrey Laurence
Journal of Clinical Investigation (2022) Vol. 132, Iss. 15
Open Access | Times Cited: 102
Accelerating antiviral drug discovery: lessons from COVID-19
Annette von Delft, Matthew D. Hall, Ann D. Kwong, et al.
Nature Reviews Drug Discovery (2023) Vol. 22, Iss. 7, pp. 585-603
Open Access | Times Cited: 94
Dual Antiviral Therapy for Persistent Coronavirus Disease 2019 and Associated Organizing Pneumonia in an Immunocompromised Host
Caitlin A. Trottier, Beverly Wong, Rakhi Kohli, et al.
Clinical Infectious Diseases (2022) Vol. 76, Iss. 5, pp. 923-925
Open Access | Times Cited: 71
Nucleoside‐Based Drug Target with General Antimicrobial Screening and Specific Computational Studies against SARS‐CoV‐2 Main Protease
Sarkar M. A. Kawsar, Md. Ahad Hossain, Supriyo Saha, et al.
ChemistrySelect (2024) Vol. 9, Iss. 15
Closed Access | Times Cited: 23
Multiple redox switches of the SARS-CoV-2 main protease in vitro provide opportunities for drug design
Lisa-Marie Funk, Gereon Poschmann, Fabian Rabe von Pappenheim, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 15
An intranasal ASO therapeutic targeting SARS-CoV-2
Chi Zhu, Justin Y. Lee, Jia Z. Woo, et al.
Nature Communications (2022) Vol. 13, Iss. 1
Open Access | Times Cited: 61
Drug Combinations as a First Line of Defense against Coronaviruses and Other Emerging Viruses
Judith M. White, Joshua T. Schiffer, Rachel Bender Ignacio, et al.
mBio (2021) Vol. 12, Iss. 6
Open Access | Times Cited: 57
Bioactive natural products in COVID-19 therapy
Zhonglei Wang, Ning Wang, Liyan Yang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 56
Immunocompromised Patients with Protracted COVID-19: a Review of “Long Persisters”
M. Veronica Dioverti, Sonsoles Salto‐Alejandre, Ghady Haidar
Current Transplantation Reports (2022) Vol. 9, Iss. 4, pp. 209-218
Open Access | Times Cited: 56
Lethal Mutagenesis of RNA Viruses and Approved Drugs with Antiviral Mutagenic Activity
Ikbel Hadj Hassine, Manel Ben M’hadheb-Gharbi, Luis Menéndez‐Arias
Viruses (2022) Vol. 14, Iss. 4, pp. 841-841
Open Access | Times Cited: 42
Monkeypox outbreak 2022: What we know so far and its potential drug targets and management strategies
Ali A. Rabaan, Abdul Hawil Abas, Trina Ekawati Tallei, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Closed Access | Times Cited: 40
Inhibition of cellular RNA methyltransferase abrogates influenza virus capping and replication
Yuta Tsukamoto, Takahiro Hiono, Shintaro Yamada, et al.
Science (2023) Vol. 379, Iss. 6632, pp. 586-591
Open Access | Times Cited: 29
Surface molecularly imprinted polymer/covalent organic framework/silica composite material with specific recognition ability and excellent chromatographic performance
Yuanfei Liu, Lulu Zhao, Yanjuan Liu, et al.
Talanta (2024) Vol. 276, pp. 126238-126238
Closed Access | Times Cited: 11
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
SARS-CoV-2 mitochondrial metabolic and epigenomic reprogramming in COVID-19
Joseph W. Guarnieri, Jeffrey Haltom, Yentli E. Soto Albrecht, et al.
Pharmacological Research (2024) Vol. 204, pp. 107170-107170
Open Access | Times Cited: 9
A Broad Antiviral Strategy: Inhibitors of Human DHODH Pave the Way for Host-Targeting Antivirals against Emerging and Re-Emerging Viruses
Yucheng Zheng, Shiliang Li, Kun Song, et al.
Viruses (2022) Vol. 14, Iss. 5, pp. 928-928
Open Access | Times Cited: 36
Combinations of Host- and Virus-Targeting Antiviral Drugs Confer Synergistic Suppression of SARS-CoV-2
Jessica Wagoner, Shawn Herring, Tien-Ying Hsiang, et al.
Microbiology Spectrum (2022) Vol. 10, Iss. 5
Open Access | Times Cited: 34
Mono- and combinational drug therapies for global viral pandemic preparedness
Aleksandr Ianevski, Rouan Yao, Ronja M. Simonsen, et al.
iScience (2022) Vol. 25, Iss. 4, pp. 104112-104112
Open Access | Times Cited: 30
Attenuation of SARS‐CoV‐2 replication and associated inflammation by concomitant targeting of viral and host cap 2'‐O‐ribose methyltransferases
Valter Bergant, Shintaro Yamada, Vincent Grass, et al.
The EMBO Journal (2022) Vol. 41, Iss. 17
Open Access | Times Cited: 29
Antiviral combination therapies for persistent COVID-19 in immunocompromised patients
Daniele Focosi, Fabrizio Maggi, Alessandra D’Abramo, et al.
International Journal of Infectious Diseases (2023) Vol. 137, pp. 55-59
Open Access | Times Cited: 17
Repurposing Drugs for the Treatment of COVID-19 and Its Cardiovascular Manifestations
Rui‐Sheng Wang, Joseph Loscalzo
Circulation Research (2023) Vol. 132, Iss. 10, pp. 1374-1386
Open Access | Times Cited: 16
Developing nucleoside tailoring strategies against SARS-CoV-2 via ribonuclease targeting chimera
Yuan‐Qin Min, Wei Xiong, Wei Shen, et al.
Science Advances (2024) Vol. 10, Iss. 15
Open Access | Times Cited: 6
3D-printed airway model as a platform for SARS-CoV-2 infection and antiviral drug testing
Yunji Lee, Myoung Kyu Lee, Hwa‐Rim Lee, et al.
Biomaterials (2024) Vol. 311, pp. 122689-122689
Closed Access | Times Cited: 5
Page 1 - Next Page

Scroll to top